Predicted protein targets (top 20)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | LMNA | P02545 | 4/20 | 0.39 |
| ▸ | ALDH1A1 | P00352 | 4/20 | 0.37 |
| ▸ | KDM4E | B2RXH2 | 3/20 | 0.37 |
| ▸ | GLA | P06280 | 2/20 | 0.37 |
| ▸ | GAA | P10253 | 2/20 | 0.37 |
| ▸ | SMN1; SMN2 | Q16637 | 6/20 | 0.36 |
| ▸ | MEN1 | O00255 | 3/20 | 0.36 |
| ▸ | KMT2A | Q03164 | 3/20 | 0.36 |
| ▸ | NPC1 | O15118 | 1/20 | 0.36 |
| ▸ | PKM | P14618 | 1/20 | 0.36 |
| ▸ | RAB9A | P51151 | 1/20 | 0.36 |
| ▸ | MTNR1A | P48039 | 1/20 | 0.36 |
| ▸ | CYP3A4 | P08684 | 3/20 | 0.36 |
| ▸ | MAPT | P10636 | 3/20 | 0.36 |
| ▸ | TP53 | P04637 | 2/20 | 0.36 |
| ▸ | TTR | P02766 | 1/20 | 0.36 |
| ▸ | MAPK1 | P28482 | 1/20 | 0.36 |
| ▸ | CA2 | P00918 | 1/20 | 0.36 |
| ▸ | CA5A | P35218 | 1/20 | 0.36 |
| ▸ | ADRA2A | P08913 | 1/20 | 0.35 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL4298902 | 1.00 | LMNA (0.39) | LMNAALDH1A1KDM4EGLAGAA | |
| SCHEMBL3955057 | 1.00 | LMNA (0.39) | LMNAALDH1A1KDM4EGLAGAA | |
| SCHEMBL6941593 | 1.00 | LMNA (0.39) | LMNAALDH1A1KDM4EGLAGAA | |
| SCHEMBL2070801 | 0.88 | CYP3A4 (0.43) | LMNAALDH1A1KDM4EGLAGAA | |
| SCHEMBL1725625 | 0.82 | CYP3A4 (0.44) | LMNAALDH1A1KDM4EGLAGAA | |
| SCHEMBL1724274 | 0.82 | CYP3A4 (0.44) | LMNAALDH1A1KDM4EGLAGAA | |
| SCHEMBL2070082 | 0.82 | CYP3A4 (0.44) | LMNAALDH1A1KDM4EGLAGAA | |
| SCHEMBL1724275 | 0.82 | CYP3A4 (0.44) | LMNAALDH1A1KDM4EGLAGAA | |
| SCHEMBL12993092 | 0.80 | LMNA (0.44) | LMNAALDH1A1KDM4EGLAGAA | |
| SCHEMBL12992985 | 0.80 | LMNA (0.44) | LMNAALDH1A1KDM4EGLAGAA |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 10 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-20090233999-A1 | COMPOSITIONS AND THERAPEUTIC METHODS INVOLVING ISOFLAVONES AND ANALOGUES THEREOF | NOVOGEN RESEARCH PTY LTD (AU) | 2009-09-17 | — | — | US | disclosed |
| US-7488494-B2 | Compositions and therapeutic methods involving isoflavones and analogues thereof | NOVOGEN RESEARCH PTY LTD. (AU) | 2009-02-10 | — | — | US | disclosed |
| US-20080014249-A1 | Compositions and therapeutic methods involving isoflavones and analogues thereof | NOVOGEN RESEARCH PTY LTD. | 2008-01-17 | — | — | US | disclosed |
| EP-1721903-A1 | Compositions and therapeutic methods involving isoflavones and analogues thereof | Novogen Research Pty. Ltd. (AU) | 2006-11-15 | — | — | EP | disclosed |
| EP-1210341-B1 | COMPOSITIONS AND THERAPEUTIC METHODS INVOLVING ISOFLAVONES AND ANALOGUES THEREOF | NOVOGEN RES PTY LTD (AU) | 2006-08-02 | — | — | EP | disclosed |
| US-20060106220-A1 | Compositions and therapeutic methods involving isoflavones and analogues thereof | NOVOGEN RESEARCH PTY. LTD. | 2006-05-18 | — | — | US | disclosed |
| US-20040147551-A1 | Compositions and therapeutic methods involving isoflavones and analogues thereof | NOVOGEN RESEARCH PTY LTD. | 2004-07-29 | — | — | US | disclosed |
| EP-1210341-A4 | COMPOSITIONS AND THERAPEUTIC METHODS INVOLVING ISOFLAVONES AND ANALOGUES THEREOF | NOVOGEN RES PTY LTD (AU) | 2003-06-11 | — | — | EP | disclosed |
| EP-1210341-A1 | COMPOSITIONS AND THERAPEUTIC METHODS INVOLVING ISOFLAVONES AND ANALOGUES THEREOF | Novogen Research Pty. Ltd. (AU) | 2002-06-05 | — | — | EP | disclosed |
| WO-2001017986-A1 | COMPOSITIONS AND THERAPEUTIC METHODS INVOLVING ISOFLAVONES AND ANALOGUES THEREOF | NOVOGEN RESEARCH PTY LTD (AU) | 2001-03-15 | — | — | WO | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (4 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20060106220-A1 | Compositions and therapeutic methods involving isoflavones and analogues thereof | SHBG, OAT, APOB | LMNA 702/4885ALDH1A1 3385/4885KDM4E 3617/4885 |
| US-20080014249-A1 | Compositions and therapeutic methods involving isoflavones and analogues thereof | SHBG, ESR2, GPER1 | LMNA 2996/4885ALDH1A1 2374/4885KDM4E 3654/4885 |
| US-20090233999-A1 | COMPOSITIONS AND THERAPEUTIC METHODS INVOLVING ISOFLAVONES AND ANALOGUES THEREOF | SHBG, OAT, APOB | LMNA 702/4885ALDH1A1 3385/4885KDM4E 3617/4885 |
| US-20040147551-A1 | Compositions and therapeutic methods involving isoflavones and analogues thereof | SHBG, ESR2, GPER1 | LMNA 3066/4885ALDH1A1 2034/4885KDM4E 3252/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.